Vircell Exhibits Its New VirClia Lotus and qSPEED-OLIGO Systems at MEDLAB
|
By LabMedica International staff writers Posted on 05 Feb 2020 |

Illustration
Vircell (Granada, Spain) exhibited its new instruments, VirClia Lotus and qSPEED-OLIGO, at MEDLAB Middle East, an event for showcasing the latest technology and knowledge in the IVD and medical laboratory market that was held at the Dubai International Convention and Exhibition Centre from February 3-6, 2020.
Vircell is a microbial biotechnology company which develops, manufactures and markets ready-to-use kits for the diagnosis of esoteric infectious diseases. It is specialized in the development and production of ready-to-use reagents for the diagnosis of infectious diseases in humans by different techniques – ranging from the traditional cell culture to the most innovating developments in the field of molecular biology.
At this year’s MEDLAB Middle East, Vircell exhibited VirClia Lotus, its new Chemiluminescence system (CLIA) designed to process diagnostic immunoassays VirClia Monotest. The VirClia Lotus CLIA system offers random access with continuous loading, STAT function to manage urgent samples, and positive identification of samples and strips through an internal scanner. It delivers the firsts results in one hour (new result every 30 seconds), 40 tests in one hour 25 minutes, and 80 tests in two hours 30 minutes with a capacity of 50 primary tubes and/or aliquots.
Vircell also presented its new approach on molecular biology, the qSPEED-OLIGO which is a unique molecular diagnostic tool for real-time PCR multiplex testing of infectious diseases and offers automated identification of positive samples. The qSPEED-OLIGO system includes a two-channel fluorescence thermocycler which allows for the screening of all pathogens (FAM) and for the internal control and sample validation (HEX). It helps rapidly discard negatives and focus only on identifying positive samples. The benchtop modular instrument increases laboratory throughput with automated screening of 48 samples in less than 90 minutes. It provides the advantage of minimum hands-on-time protocol by using pre-dispensed qPCR tubes and sealed cassettes to rule out contamination.
Related Links:
Vircell
Vircell is a microbial biotechnology company which develops, manufactures and markets ready-to-use kits for the diagnosis of esoteric infectious diseases. It is specialized in the development and production of ready-to-use reagents for the diagnosis of infectious diseases in humans by different techniques – ranging from the traditional cell culture to the most innovating developments in the field of molecular biology.
At this year’s MEDLAB Middle East, Vircell exhibited VirClia Lotus, its new Chemiluminescence system (CLIA) designed to process diagnostic immunoassays VirClia Monotest. The VirClia Lotus CLIA system offers random access with continuous loading, STAT function to manage urgent samples, and positive identification of samples and strips through an internal scanner. It delivers the firsts results in one hour (new result every 30 seconds), 40 tests in one hour 25 minutes, and 80 tests in two hours 30 minutes with a capacity of 50 primary tubes and/or aliquots.
Vircell also presented its new approach on molecular biology, the qSPEED-OLIGO which is a unique molecular diagnostic tool for real-time PCR multiplex testing of infectious diseases and offers automated identification of positive samples. The qSPEED-OLIGO system includes a two-channel fluorescence thermocycler which allows for the screening of all pathogens (FAM) and for the internal control and sample validation (HEX). It helps rapidly discard negatives and focus only on identifying positive samples. The benchtop modular instrument increases laboratory throughput with automated screening of 48 samples in less than 90 minutes. It provides the advantage of minimum hands-on-time protocol by using pre-dispensed qPCR tubes and sealed cassettes to rule out contamination.
Related Links:
Vircell
Latest MEDLAB 2020 News
- Diagnostica Stago Displays STA Compact Max and STA Satellite Max Analyzers at MEDLAB
- DAS Srl Exhibits Range of Fully Automated Systems at MEDLAB Middle East 2020
- GeneMatrix Promotes Sex and Respiratory Infection Testing Products at MEDLAB
- Mindray Showcases Comprehensive IVD Solutions Portfolio at MEDLAB Middle East 2020
- New Technology that Detects MRSA in 15 Minutes Introduced at MEDLAB Middle East 2020
- Randox Showcases New All-In-One Solution for Molecular Diagnostics at MEDLAB Middle East 2020
- EKF Diagnostics Displays POC Analyzers for Hemoglobin, HbA1c And Lactate at MEDLAB Middle East
- Erba Mannheim Launches New Electrolyte Analyzer with Maintenance-free Electrodes at MEDLAB 2020
- MEDLAB Middle East 2020 Addresses Future of Laboratory Medicine
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








